MEP and Neuromuscular Blocker
- Conditions
- Brain Tumor
- Interventions
- Drug: Arm I (MEP)
- Registration Number
- NCT04768400
- Lead Sponsor
- Gangnam Severance Hospital
- Brief Summary
It is important to predict the influence of the neuromuscular blocking agents on the motor evoked potential. Investigator will investigate the dose-response relationship between the degree of the neuromuscular blockade and the motor evoked potential in patients undergoing brain tumor surgery using the population approach. Investigator will investigate the influence of the other factors such as the impedence, reactance, muscel amount, and age on the motor evoked potential.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
- Patients aged 19 years old or older, with American Society of Anesthesiologists Physical Status 1-3, and scheduled for elective brain tumor surgery under the monitoring of the motor evoked potential
- Central or peripheral neuromuscular disease
- Sensory or motor nerve disorder
- Allergy to propofol, remifentanil, and rocuronium
- Patients with pacemaker
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description rocuronium Arm I (MEP) Neuromuscular blockade will be performed using rocuronium.
- Primary Outcome Measures
Name Time Method Amplitude of the motor evoked potential At intraoperative 0 hr from the start of the anesthetic induction Amplitude of the motor evoked potential will be evaluated at intraoperative 0 h from the start of the anesthetic induction.
- Secondary Outcome Measures
Name Time Method Amplitude of the motor evoked potential At intraoperative 0 h from the opening of the dura Amplitude of the motor evoked potential will be evaluated at intraoperative 0 h from the opening of the dura.
Trial Locations
- Locations (1)
GangnamSeverance Hospital
🇰🇷Seoul, Korea, Republic of